Search Thermo Fisher Scientific
- Contáctenos
- Orden Rápida
-
¿No tiene una cuenta? Crear una cuenta
Oncomine Childhood Cancer Research Assay
Because childhood and young adult cancer is different
The types and driving genetic aberrations of these malignancies are different than those affecting the adult population, so a specifically designed, targeted but comprehensive panel is needed to advance clinical research and drive understanding and future precision oncology therapeutic solutions.
The Ion Torrent Oncomine Childhood Cancer Research Assay is a next-generation sequencing (NGS)-based tool designed for comprehensive genomic profiling of cancers affecting children and young adults.
Comprehensive panel design:
- Compiled by leading researchers and pediatric oncologists
- 203 unique genes including thousands of fusion drivers (and comprehensive mutation coverage)
Optimised workflow for fast results:
- End-to-end solution including informatics
- 2–3 days, depending on sample type
- Compatible with different sample types enabled including blood, bone marrow, and FFPE tissue
Covers relevant targets for a broad range of malignancies affecting children and adults:
- Childhood leukemias
- Lymphomas
- Sarcomas
- Central nervous system and brain neoplasms
Featured videos
Understanding pediatric and childhood cancers
NGS research panels for pediatric cancer
Read the latest interview with Dr. Tim Triche featured in the Pathologist
The Oncomine Childhood Cancer Research Assay is the first cancer panel designed for all forms of childhood cancer, including leukemia, brain tumors, and a diverse group of solid tumors. Of particular importance, it assays both RNA and DNA, which allows one to detect both gene fusions and DNA mutations, both of which are important in childhood cancer.
Timothy Triche, MD, PhD
Founding Director of the Children’s Hospital Los Angeles Center for Personalized Medicine
Oncomine Childhood Cancer Research workflow
The end-to-end workflow optimized for childhood cancer research enables the analysis of a variety of sample types including blood and bone marrow, fresh/frozen tissue, and FFPE tissue in 2–3 days from sample to result. Up to eight samples can be multiplexed on a single Ion 540 Chip*, allowing for flexibility in batch size.
Comprehensive mutation coverage (86) | ||
| ABL1 ABL2 ALK ACVR1 AKT1 ASXL1 ASXL2 BRAF CALR CBL CCND1 CCND3 CCR5 CDK4 CIC CREBBP CRLF2 CSF1R CSF3R CTNNB1 DAXX DNMT3A EGFR EP300 ERBB2 ERBB3 ERBB4 ESR1 EZH2 | FASLG FBXW7 FGFR1 FGFR2 FGFR3 FLT3 GATA2 GNA11 GNAQ H3F3A HDAC9 HIST1H3B HRAS IDH1 IDH2 IL7R JAK1 JAK2 JAK3 KDM4C KDR KIT KRAS MAP2K1 MAP2K2 MET MPL MSH6 MTOR MYC MYCN | NCOR2 NOTCH1 NPM1 NRAS NT5C2 PAX5 PDGFRA PDGFRB PIK3CA PIK3R1 PPM1D PTPN11 RAF1 RET RHOA SETBP1 SETD2 SH2B3 SH2D1A SMO STAT3 STAT5B TERT TPMT USP7 ZMYM3 |
Full exon coverage(44) | |
| APC ARID1A ARID1B ATRX CDKN2A CDKN2B CEBPA CHD7 CRLF1 DDX3X DICER1 EBF1 EED FAS GATA1 GATA3 GNA13 ID3 IKZF1 KDM6A KMT2D MYOD1 NF1 NF2 PHF6 PRPS1 PSMB5 PTCH1 | PTEN RB1 RUNX1 SMARCA4 SMARCB1 SOCS2 SUFU SUZ12 TCF3 TET2 TP53 TSC1 TSC2 WHSC1 WT1 XIAP |
CNV (28) |
| ABL2 ALK BRAF CCND1 CDK4 CDK6 EGFR ERBB2 ERBB3 FGFR1 FGFR2 FGFR3 FGFR4 GLI1 GLI2 IGF1R JAK1 JAK2 JAK3 KIT KRAS MDM2 MDM4 MET MYC MYCN PDGFRA PIK3CA |
Fusion and expression (98) | |||
| ABL1 ABL2 AFF3 ALK BCL11B BCOR BCR BRAF CAMTA1 CCND1 CIC CREBBP CRLF2 CSF1R DUSP22 EGFR ETV6 EWSR1 FGFR1 FGFR2 FGFR3 FLT3 FOSB FUS GLI1 GLIS2 HMGA2 | JAK2 KAT6A KMT2A KMT2B KMT2C KMT2D LMO2 MAML2 MAN2B1 MECOM MEF2D MET MKL1 MLLT10 MN1 MYB MYBL1 MYH11 MYH9 NCOA2 NCOR1 NOTCH1 NOTCH2 NOTCH4 NPM1 NR4A3 | NTRK1 NTRK2 NTRK3 NUP214 NUP98 NUTM1 NUTM2B PAX3 PAX5 PAX7 PDGFB PDGFRA PDGFRB PLAG1 RAF1 RANBP17 RARA RECK RELA RET ROS1 RUNX1 SS18 SSBP2 STAG2 STAT6 | TAL1 TCF3 TFE3 TP63 TSLP TSPAN4 UBTF USP6 WHSC1 YAP1 ZMYND11 ZNF384 Gene Expression |
>1700 fusion isoform variants
The content of the Oncomine Childhood Research Assay has been developed with leading scientists and pediatric oncologists. It includes a large 97-gene translocation/fusion panel (>1700 fusion isophorme variants), as fusions are relatively more common in childhood sarcomas and leukemias, but also an 82-DNA target panel with comprehensive coverage of all relevant mutations, 44 targets with full exon coverage, specifically tumor supressor genes, and 24 CNV targets.
| Catalog Number | ||
| Oncomine Childhood Cancer Research Assay | Chef-ready library | Learn more and request quote › |
| Oncomine Childhood Cancer Research Assay | Manual library | Learn more and request quote › |
*The assay has been optimized and verified for the Ion 540 Chip.
For Research Use Only. Not for use in diagnostic procedures.